18.5 billion sedation sleep market top 10 varieties momentum!

Sleep is an important part of improving human immune function Good sleep habits are very important When we can't get enough sleep under the influence of various pathological and psychological factors, drugs play an important role With the improvement of sleep management consciousness in modern society, the market of sleeping pills has made great progress Overview the data of the continuous expansion of the market scale of mental stability shows that the market scale of domestic mental stability drugs in 2016 was RMB 17.33 billion According to the data forecast of the first three quarters of 2017, the market scale of domestic psychostatic drugs in 2017 will reach 18.505 billion yuan, an increase of 6.78% over 2016 According to the statistics of the World Health Organization, about a quarter of people suffer from insomnia In addition, according to the survey of the society of psychiatry of the Chinese Medical Association, the poor sleep quality of the middle-aged and elderly in China has exceeded 40%, which has become a relatively common social problem, and has further promoted the market of sedative and sleeping drugs and health care products, thus attracting the attention of many businesses Top 10 accounts for 99% of the drugs commonly used in domestic clinical sedation and hypnosis are: the first generation of barbiturates, the second generation of benzodiazepines, the third generation of non benzodiazepines, and cyclopyrrolidone hypnotics At present, no sedative is absolutely superior to other drugs There are 10 hypnotic and sedative drugs and 7 anti anxiety chemicals in the 2017 national basic medical insurance catalogue There are more than 20 kinds of related drugs used in the hospital market According to the data of minenet, in 2016, the market scale of sedative and hypnotic drugs in public hospitals in key cities in China reached 658 million yuan, an increase of 33.14% over the previous year According to the data forecast of the first three quarters of 2017, the market scale of sedative and hypnotic drugs in public hospitals in key cities in China will reach 822 million yuan in 2017, an increase of 24.89% over the previous year The top 10 sedative and hypnotic drugs in the domestic sample hospital market are: dexmedetomidine, midazolam, zolpidem, oxazepam, right zopiclone, estazolam, zopiclone, lorazepam, alprazolam and clonazepam The top 10 occupies 99% of the total market of sedative and hypnotic drugs In recent years, on the basis of the traditional Chinese patent medicine of tranquilizing the mind and tonifying the brain, many new varieties have been developed and put on the market, which has a good effect on neurasthenia and insomnia, thus promoting the continuous growth of the domestic market A large variety of dexmedetomidine increased steadily Hengrui product was approved to be listed in the United States Dexmedetomidine injection is a α 2-adrenergic receptor agonist developed by Orion Pharma Company of Finland and abott company of the United States It was approved to be listed by FDA in March 2000, and its trade name is precedex In 2016, the global sales volume of right metoclopramide was set at US $506 million In 2009, right medetomidine of Hengrui pharmaceutical was first listed in China It was registered by FDA in the United States at the end of 2017 and will be listed in the United States At present, China has approved Hengrui, Enhua, Chenxin and Sichuan Guorui to produce the product Dexmedetomidine is more selective, with short half-life and small dosage It is clinically suitable for sedation and hypnosis of patients who start intubation and use ventilator during intensive care treatment As a result of higher safety and less side effects, it has led to a stable increase in the dosage According to the data of minenet, in 2016, the amount of dexmedetomidine in public hospitals in key cities reached 427 million yuan, an increase of 41.17% over the previous year Jiangsu Hengrui accounts for 89.14%, Sichuan Guorui for 6.32%, Jiangsu Enhua for 4.24%, and Chenxin pharmaceutical for 0.3% The overall domestic market scale is 1.04 billion yuan According to the data forecast of the first three quarters of 2017, in 2017, the amount of right metoclopramide used in public hospitals in key cities in China was 544 million yuan, an increase of 27.25% over the previous year The total domestic market size is more than 1.2 billion yuan Midazolam increased by 13.64% Midazolam is the second generation of benzodiazepines in the domestic drug monopoly market, which has the effects of anti anxiety, hypnosis, anti convulsion, muscle relaxation and anterograde amnesia In December 1985, FDA approved the launch of midazolam from Roche, Switzerland, under the trade name of versed With the expiration of patent protection and the introduction of the third generation of sedative and hypnotic drugs, midazolam has been converted into a generic drug and sold in many countries In 1998, after the successful development of domestic midazolam, Jiangsu Enhua pharmaceutical's midazolam API, its injections and tablets were approved for marketing, with the trade name of Liyuexi At present, midazolam is listed in four domestic enterprises In addition to Enhua pharmaceutical, there are also Dormicum of Roche, Zhejiang Jiuxu pharmaceutical and midazolam injection of Yichang humanwell pharmaceutical According to the data of mienei.com, in 2016, the amount of midazolam used in public hospitals in key cities reached 83.79 million yuan, an increase of 10.72% over the previous year Among them, Jiangsu Enhua accounted for 94.95%, Yichang humanwell for 3.9%, Roche for 1.02%, and Zhejiang Jiuxu pharmaceutical for 0.13% Domestic midazolam has monopolized the market According to the data forecast of the first three quarters of 2017, the amount of midazolam used in public hospitals in key cities in 2017 was 95.22 million yuan, an increase of 13.64% over the previous year, and the overall domestic market size was more than 500 million yuan Right zopiclone and zopiclone compete on the same platform Zopiclone is the third generation of sedative and hypnotic agent developed by Ronald Planck in France Now it is a product of Sanofi, with the trade name of Imovane Zopiclone has good sedative and anti anxiety effects, and is an ideal sedative and sleeping drug Right zopiclone is the right-handed isomer of zopiclone, which was developed by sepracor In 2004, the U.S FDA approved the listing of youzopiclone, with the trade name of lunesta, which was sold by sunovion company Right zopiclone hit the market of zolpidem and zopiclone after its launch, with its sales peak exceeding US $600 million After generic drugs went on the market, the original research drug market gradually declined In the 1990s, zopiclone has entered the clinical practice of our country and belongs to the class B product of national medical insurance In China, zopiclone tablets and capsules are listed The imported drugs are the memory of sanchen of Qilu pharmaceutical, Jinmeng of Jinheng of Jilin, simonhuan of Shunfeng of Guangdong China Resources, qingerqi of Tianjin Huajin, zopiclone tablet of Shanghai Xinyi balance, etc Zopiclone is a sedative and hypnotic drug commonly used in community hospitals In 2016, the market scale of zopiclone, a public hospital in key cities in China, was 17.93 million yuan, an increase of 13.77% over the previous year It is estimated from January to March 2017 that the amount of zopiclone used in public hospitals in key cities in 2017 was 22.4 million yuan, an increase of 13.54% over the previous year Right zopiclone is better than blue There are products of Tianshili group, Chengdu Kanghong Pharmaceutical Co., Ltd and Shanghai Shangyao group in youzopiclone The affinity of r-zopiclone to benzodiazepine receptor is 50 times that of l-zopiclone, which has the advantages of high efficacy and low toxicity, thus driving the rapid growth of the market In 2016, the amount of drug used by youzopiclone in public hospitals in key cities in China was 19.46 million yuan, an increase of 33.38% over the previous year According to the data forecast for the first three quarters of 2017, the amount of drug used by youzopiclone in public hospitals in key cities in 2017 was 24.13 million yuan, an increase of 24.01% over the previous year Right zopiclone has become a fast-growing variety since it came into the market It will bring new choices for different drugs and lead to the reshuffle of sedative and hypnotic drugs market Estazolam is a derivative of benzodiazepine (BDZ) It was developed in Japan in 1970s In the U.S market, it is sold by Abbott under the trade name prosom Estazolam is a short acting BDZ sedative, hypnotic and antianxiety drug Its sedative and hypnotic effect is 2.4-4 times stronger than that of nitrazepam It can be used to treat insomnia, anxiety, anticonvulsion, epilepsy and other diseases It can also be used as pre-operative medicine Generally, oral dosage form is used The drug can act on the limbic system and the reticular structure of brain stem, reduce the oxidation process of brain tissue and strengthen the protective inhibition of brain It has the characteristics of strong effect, small dosage and no aftereffect In the early 1980s, Hubei pharmaceutical factory developed eszolam API and its tablets, which were listed in China under the trade name of "Shule anding" In September 1984, Shule anding film won the national silver award certificate issued by the former State Economic and Trade Commission At present, it is the backbone variety of Hubei Huazhong Pharmaceutical Co., Ltd In the current era of new sleeping drugs, which are low-cost varieties of this kind of drugs, are the main sedative and sleeping drugs in domestic urban community medical institutions According to the data on CFDA website, there are 70 production approvals of estazolam The main manufacturers of API are Hubei Huazhong Pharmaceutical Co., Ltd., Changzhou No.4 Pharmaceutical Co., Ltd., Shandong Xinyi Pharmaceutical Co., Ltd and Shanxi xinbaoyuan Pharmaceutical Co., Ltd In 2016, the amount of estazolam used in public hospitals in key cities in China was 19.08 million yuan, an increase of 54.49% over the previous year According to the data forecast of the first three quarters of 2017, the amount of estazolam used in public hospitals in key cities in 2017 was 22.74 million yuan, an increase of 19.18% over the previous year